(Total Views: 547)
Posted On: 01/26/2022 3:42:40 PM
Post# of 155902
Ohm,
Agree that criteria should be alleviation of symptoms.
However, it may be that some symptoms are amenable to treatment and some not.
Which symptoms?
How to quantify symptom resolution?
What are inclusion and exclusion criteria?
Outside looking in seems very, very murky.
Cytodyn and patients will not benefit by rushing. I’m pleased the Dr Recknor observed biochemical markers that correlated with symptom resolution, providing a concrete foundation to design P3.
It nonetheless seems that treating and demonstrating efficacy in acute illness is more straightforward.
With PASC incidence likely increasing with the explosion of omicron-driven cases, I’m sure the FDA will set criteria, both for Cytodyn and others. Until then, continue addressing acute illness,
Agree that criteria should be alleviation of symptoms.
However, it may be that some symptoms are amenable to treatment and some not.
Which symptoms?
How to quantify symptom resolution?
What are inclusion and exclusion criteria?
Outside looking in seems very, very murky.
Cytodyn and patients will not benefit by rushing. I’m pleased the Dr Recknor observed biochemical markers that correlated with symptom resolution, providing a concrete foundation to design P3.
It nonetheless seems that treating and demonstrating efficacy in acute illness is more straightforward.
With PASC incidence likely increasing with the explosion of omicron-driven cases, I’m sure the FDA will set criteria, both for Cytodyn and others. Until then, continue addressing acute illness,
(5)
(0)
